女性在骨科各亚专业临床试验领导层中的代表性不均
该回顾性分析纳入2007至2025年ClinicalTrials.gov注册的1510项骨科临床试验,按亚专业和PI性别分析发现女性PI比例因亚专业而异(p < 0.001),小儿骨科最高(20% [19 of 95])、运动医学最低(4% [7 of 172]);按各亚专业女性外科医生占比校正后,女性在足踝、创伤、小儿、手、肩肘、肿瘤和运动医学试验领导层中比例不足,在脊柱过代表,在髋膝比例相当。
要点
- 女性PI比例因亚专业不同而异,小儿骨科最高(20%),运动医学最低(4%)。
- 校正各亚专业女性医生占比后,足踝(PPR = 0.20)、创伤(PPR = 0.51)等比例不足。
- 脊柱女性PI过代表(PPR = 1.27),髋膝比例相当(PPR = 0.83)。
核心结论
- 女性在骨科临床试验领导层的比例不足集中于特定亚专业,针对这些亚专业的PI培养举措可能比全领域通用措施更有效。
研究设计与样本
- 回顾性分析2007至2025年ClinicalTrials.gov注册的骨科临床试验,手工审核亚专业相关性与PI身份,PI性别由genderize.io判定。
- 5842项初筛试验中26%(1510 of 5842)符合纳入标准,其中55%(837 of 1510)为美国研究、42%(637 of 1510)为国际研究。
- 采用卡方检验比较九个骨科亚专业及五类干预措施的女性PI比例,美国专项分析采用患病率与参与率比值(PPR)。
- PPR < 0.80判定为代表性不足,PPR > 1.20判定为过代表,各亚专业女性医生占比通过审阅住院医师培训项目所属机构的公开网站获得。
主要发现
- 试验领导层性别构成因亚专业而异(p < 0.001),小儿骨科女性领导比例最高(20% [19 of 95]),运动医学最低(4% [7 of 172])。
- 校正各亚专业女性医生占比后,女性在足踝(PPR = 0.20)、创伤(PPR = 0.51)、小儿(PPR = 0.58)、手(PPR = 0.38)、肩肘(PPR = 0.795)、肿瘤(PPR = 0.72)和运动医学(PPR = 0.71)试验领导层中比例不足。
- 女性在脊柱试验领导层中过代表(PPR = 1.27),在髋膝中比例相当(PPR = 0.83)。
- 性别构成因世界区域而异(p = 0.02),欧洲女性研究者比例最高(12% [45 of 378]),欧洲、亚洲和美洲以外地区最低(0% [0 of 27])。
- 性别构成因干预类型而异(p < 0.001),行为干预试验女性PI比例最高(29% [12 of 41]),器械试验最低(6% [22 of 373]);观察性研究女性领导比例(11% [41 of 380])高于干预性研究(7% [82 of 1130])(p = 0.03)。
关键数值与推荐
- 代表性不足判定阈值:某性别领导的试验少于按其 workforce 份额预期80%(PPR < 0.80);过代表为超过预期120%(PPR > 1.20)。
- 儿童骨科试验女性PI比例为20%(19 of 95),运动医学为4%(7 of 172)。
- 足踝PPR = 0.20、创伤PPR = 0.51、小儿PPR = 0.58、手PPR = 0.38、肩肘PPR = 0.795、肿瘤PPR = 0.72、运动医学PPR = 0.71、脊柱PPR = 1.27、髋膝PPR = 0.83。
- 欧洲女性研究者比例为12%(45 of 378),其他地区为0%(0 of 27)。
- 行为干预试验女性PI比例为29%(12 of 41),器械试验为6%(22 of 373);观察性研究为11%(41 of 380),干预性研究为7%(82 of 1130)。
临床怎么用
- 提示在足踝、创伤、小儿、手、肩肘、肿瘤和运动医学等代表性不足的亚专业中,可优先开展针对女性的PI培养举措。
- 脊柱等比例相当或过代表的亚专业可作为可借鉴的模式,用于改进其他亚专业的女性试验领导代表性。
- 提升女性在试验领导中的比例有助于使骨科研究领导层反映 workforce 与患者的性别多样性,并加强女性骨科医生的学术成长通道。
局限性
- PI性别由genderize.io预测,低置信度预测的试验被排除。
- 仅分析ClinicalTrials.gov注册试验,且仅26%(1510 of 5842)初筛试验符合纳入标准。
- 各亚专业女性医生占比通过审阅公开网站获得,可能存在不完整或偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although men substantially outnumber women in orthopaedic surgery, prior studies have demonstrated that authorship disparities persist even after adjusting for this imbalance. If comparable patterns occur in clinical trial leadership, they may hinder women's academic advancement in our field. However, to our knowledge, no studies to date have examined proportional representation in this context. QUESTIONS/PURPOSES: (1) Does the proportion of woman-led clinical trials differ among orthopaedic subspecialties? (2) Are women proportionally represented as PIs after adjusting for the percentage of women in each specialty? (3) Is the proportion of woman-led orthopaedic clinical trials associated with other characteristics, such as trial location or type of intervention? METHODS: A retrospective analysis of orthopaedic surgery clinical trials registered on ClinicalTrials.gov from 2007 to 2025 was performed. Trials were manually reviewed for subspecialty relevance and PI identity. PI gender was determined via genderize.io, a validated online application that assigns a predicted gender to user-input names. Trials without orthopaedic surgeons as PIs and those with low-confidence gender predictions via genderize.io were excluded. Of the trials initially identified, 26% (1510 of 5842) met inclusion criteria, of which 55% (837 of 1510) were US-based and 42% (637 of 1510) were international studies. Chi-square tests were used to compare the proportion of women PIs across nine orthopaedic subspecialities and five intervention types (procedural, device, drug, behavioral, and other). Chi-square tests were also used to compare representation in trial leadership across regions within the United States and across continents. A US-specific analysis utilized prevalence to participation ratios (PPRs) to assess whether there was equitable representation of women among trial leadership after normalizing to the underlying proportion of women surgeons in each subspecialty. These proportions were obtained by reviewing public websites to identify academic surgeons at institutions affiliated with orthopaedic residency programs. Subspecialties were considered to have underrepresentation of a gender when that gender led less than 80% of the trials expected based on its share of the workforce (PPR < 0.80) and overrepresentation when a gender led more than 120% of the expected trials (PPR > 1.20). RESULTS: Gender representation among trial leadership varied by subspecialty (p < 0.001), with pediatric orthopaedic trials demonstrating the highest proportion led by women (20% [19 of 95]) and sports medicine demonstrating the lowest (4% [7 of 172]). After adjusting for the underlying demographics of each subspecialty's workforce, women were proportionally underrepresented in foot and ankle (PPR = 0.20), trauma (PPR = 0.51), pediatrics (PPR = 0.58), hand (PPR = 0.38), shoulder and elbow (PPR = 0.795), oncology (PPR = 0.72), and sports medicine (PPR = 0.71) trial leadership. Women were overrepresented among trial leadership in spine (PPR = 1.27) and proportionally represented among hip and knee (PPR = 0.83) trial leadership. Gender representation varied by world region (p = 0.02), with Europe showing the highest proportion of women investigators (12% [45 of 378]) and "Other" regions (that is, those outside of Europe, Asia, and the Americas) showing the least (0% [0 of 27]). Representation also differed by study intervention (p < 0.001), with behavioral intervention trials having the highest proportion of women PIs (29% [12 of 41]) and device trials having the lowest proportion (6% [22 of 373]), and by study type (p = 0.03), as observational studies included a greater proportion of woman-led trials (11% [41 of 380]) than interventional studies (7% [82 of 1130]). CONCLUSION: As proportional underrepresentation of women in trial leadership is concentrated in specific subspecialties, PI development initiatives in these areas may have greater impact than generic, field-wide efforts. Understanding why some subspecialties have achieved proportional representation whereas others lag behind should be a priority for future work, as fields with proportional or higher-than-expected representation may provide models worth emulating. CLINICAL RELEVANCE: Improving the proportional representation of women in trial leadership roles ensures that research leadership in orthopaedics reflects the gender diversity of our workforce and our patients. Doing so may also help strengthen the academic pipeline for women orthopaedic surgeons.
引用
- Mao E, Glenn ER, Ryu D, et al. Women Are Unequally Represented Among Clinical Trial Leadership by Orthopaedic Subspecialty. Clin Orthop Relat Res. 2026. PMID: 41699696. doi:10.1097/CORR.0000000000003848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。